Abstract
Objective : To discuss and analyze the clinical effects and changes of ovarian function after GnRH-α combined with Mirena treatment in patients with adenomyosis. Methods: The research subjects in this study were all adenomyosis patients (60 cases) who were admitted to our hospital from January 2020 to June 2022. They were randomly divided into control group (30 cases, receiving Mirena treatment) and observation group (30 cases, receiving GnRH-α combined with Mirena treatment). Compare the relevant indicators of the two groups. Results: After treatment, the uterine volume of the observation group and the control group were smaller than before treatment, the thickness of endometrium was thinner than before treatment, the VAS score, PBAC score, serum FSH, LH, E2 levels were all lower than before treatment, the serum AMH level, and various FSFI scores were higher than before treatment, and the trend of the former was more obvious. The comparison of the total incidence of adverse reactions between the observation group and the control group showed that the former was lower (all P < 0.05 ). Conclusion: The application of GnRH-α combined with Mirena in patients with adenomyosis can reduce the amount of menstrual bleeding, reduce the volume of the uterus, relieve pain, promote the recovery of ovarian function, improve the quality of sexual life, and have high safety. It is worthy of extensive follow-up application.
References
[2]Dong Aihua, Liu Haiyan. Application value analysis of levonorgestrel intrauterine sustained-release system in the treatment of adenomyosis [J]. Electronic Journal of Practical Gynecology Endocrinology, 2022, 9(22): 36-38.
[3]Chen Weijing, Wang Ling, Su Xingkai, et al. Therapeutic effect of comprehensive nursing intervention combined with ultrasound-guided radiofrequency ablation, GnRH-a, and LNG-IUS on adenomyosis [J]. Hebei Medicine, 2022, 44(1): 157-160.
[4]Zhang Xiyin. Practical Obstetrics and Gynecology (2nd Edition) [M]. Beijing: People's Medical Publishing House, 2003: 245.
[5]Wang Fang, Luo Xuping, Zhang Jiaying, et al. Application of visual analogue scale in the consultation of influenza patients [J]. Chinese Journal of General Practice, 2019, 22(20): 2472-2475.
[6]Lin Peijia, Zhou Kaiqun, Yao Juanhua. Effect of Desogestrel Ethinylestradiol Tablets Combined with LNG-IUS on PBAC Score and Sex Hormone Levels in Patients with Aovulatory Abnormal Uterine Bleeding [J]. Clinical Medical Engineering, 2021, 28(4): 467-468.
[7]ZHANG Yan, SU SU, ZHENG Xiaoyi. Analysis of the Effect of Combined Application of Vaginal Hysterectomy and Vaginal Top Suspension on Female Sexual Function Index and Prognosis in Patients with Uterine Prolapse [J]. Chinese Journal of Sexology, 2020, 29(9): 96-99.
[8]Sun Aifen. Effect of Guizhi Fuling Capsules Combined with Mirena on Endometrial Thickness and Sex Hormones in Patients with Adenomyosis [J]. Liaoning Medical Journal, 2021, 35(6): 17-19.
[9]Chen Xixi, Zhou Hu, Wu Wenjun, et al. Clinical effect of HIFU combined with ultra-long-cycle half-dose GnRH-a in the treatment of adenomyosis [J]. Journal of Logistics College of Armed Police Force (Medical Science), 2021, 30(8): 71-72.
[10]Zhu Yuanyuan, Zhang Lei, Yang Yijun. Efficacy and safety evaluation of GnRH-a combined with Yasmin on hysteroscopic endometrial resection for adenomyosis [J]. Hebei Medicine, 2022, 28(8): 1303-1306.
[11]Tang Juan. Effects of uterine artery embolization with different embolization agents on dysmenorrhea pain degree and serum FSH level in patients with severe adenomyosis [J]. Electronic Journal of Practical Gynecology Endocrinology, 2021, 8(7): 16-19.
[12]Xie Tingting, Chu Bin. The curative effect of Xiaojie'an capsule combined with gestrinone in the treatment of patients with adenomyosis and its effect on serum CA125 and prostaglandin F-2a [J]. Chinese Maternal and Child Health Care, 2020, 35(3): 436-438.
[13]Wang Lijuan, Tang Chunhui. Effects of GnRH-a combined with levonorgestrel intrauterine sustained-release system on pain symptoms, serum MMPs and recurrence in patients with adenomyosis [J]. Chinese Journal of Family Planning, 2021, 29(2): 266-270+274.